1. Market Research
  2. > Pharmaceutical Market Trends
  3. > GMR Data - The Global Pre-Filled Syringe Market to 2024

GMR Data - The Global Pre-Filled Syringe Market to 2024

  • October 2014
  • -
  • GMR Data Ltd
  • -
  • 160 pages

The Global Pre-filled Syringe Market 2014-2024 report analyses how this important sub-sector will continue to grow across the next decade. The report highlights key companies, geographies and products that we believe will deliver double digit growth across the next decade.

Buy this report today and acquire analysis of the state of the pre-filled syringes market in 2014 and a market forecastfor the period 2014-2024. Market forecasts are also provided for global pre-filled syringes for glass and plastics on the global level (value and volume) as well as for the geographic regions of key pre-filled syringe types (value and volume).

The advantages that will drive the growth of pre-filled syringes include ease of administration, improved safety, reduced risk of contamination, elimination of medication errors, low incidence of needlestick injuries, accurate dosing and reduction in medical expenditure due to reduced visits to healthcare facilities.

When compared to standard injectables, the pre-filled syringes market is still evolving, and its use is slowly increasing. Developed countries have shown a strong adoption rate for pre-filled syringes whereas developing & ROW countries have often been slow in adopting this technology. During the forecast period, however, the adoption rate will witness a healthy growth in emerging markets, and will witness a growth rate above that of developed geographies such as the US and in Europe.

The market is highly consolidated and is currently dominated by key global players such as Abbott Labs, Becton Dickinson, Baxter, Nipro Corporation, Schott, Gerresheimer, West Pharmaceutical, Ypsomed, Bespak and Unilife Corporation. Other companies such as Haselmeier; Weigao Group, Nuova Ompi (Stevanato Group), Owen Mumford and Vetter Pharma are likely to foster innovation in the coming years.

The Global Pre-filled Syringe Market 2014-2024 report includes over 125 tables, charts and graphs quantifying and forecasting the market in detail. In addition, the report offers 14 profiles of the leading PFS companies in the market alongside 3 expert interviewees offering key insights into the state of the market currently and in the future;

Table Of Contents

GMR Data - The Global Pre-Filled Syringe Market to 2024
1- Executive Summary

1.1 Global Pre-filled Syringes Market Review

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

1.4 Drivers and Restraints of the Global Pre-Filled Syringe Market 2014-2024

1.4.1 Drivers

1.4.1.1 Growth of the Injectable Drugs Market

1.4.1.2 Success and Growth of Biologics

1.4.1.3 Increased Global Vaccination

1.4.1.4 Increased Drug Self-Administration

1.4.1.5 Technological Advances in the Manufacture of PFS

1.4.1.6 Advances in PFS Technology

1.4.2 Restraints

1.4.2.1 Increased Manufacturing / Distribution Costs

1.4.2.2 Alternative Drug Delivery Methods

1.4.2.3 Controlled Release



2 -Introduction to the Pre Filled Syringe Market

2.1 Introduction to Pre-filled Syringes

2.1.1 What are Pre-Filled Syringes

2.1.2 Market Overview of Pre-filled Syringes

2.1.3 An Increasingly Accessable Sector

2.1.4 Key Advances in the PFS Industry

2.2 Components of Pre-filled Syringes

2.3 Types of Pre-filled Syringes

2.3.1 Glass Syringes

2.3.2 Plastic Syringes

2.4 Classification of Pre-filled Syringes

2.4.1 Single-chamber and Dual-Chamber

2.4.2 Type of needle

2.5 Injection delivery devices

2.5.1 Pen Injectors

2.5.2 Insulin pens

2.5.3 Auto-Injectors

2.5.4 Needle-Free Injectors

2.5.5 Drugs available in Pre-filled Syringes

2.6 Concerns over needle stick Injuries



3 -Global Pre-Filled Syringe; Market Revenue and Volume Forecasts to 2024

3.1 Global Market Overview

3.1.1 Global Pre-filled Syringes Market Revenue, 2013-2024

3.1.2 Global Pre-filled Syringes Market Volume, 2013-2024

3.2 Glass Pre-filled syringes

3.2.1 Global Glass Pre-filled Syringes Market Revenue, 2013-2024

3.2.2 Global glass Pre-filled Syringes Market size, 2013 - 2024

3.3 Plastic Pre-filled syringes

3.3.1 Global Plastic Pre-filled Syringes Market Revenue, 2013 - 2024

3.3.2 Global Plastic Pre-filled Syringes Market size, 2013 - 2024



4 - Key Geographies in the Global Pre-Filled Syringe Market 2014-2024

4.1 Global Market Overview

4.2 The North America PFS Market 2013-2024

4.2.1 Key drivers in the North American PFS market

4.2.1.1 Increase in Cancer Treatment

4.2.1.2 Spending on multiple sclerosis (MS)

4.2.1.3 Increase in Diabetes Prevalence

4.2.1.4 Healthcare Expenditure

4.2.1.5 Spend on Vaccination

4.2.1.6 Regulatory Environment for Pre-Filled Syringes

4.3 The Europe PFS Market 2013-2024

4.3.1 Key factors that will drive the PFS market in Europe

4.3.1.1 Favourable reimbursement policies

4.3.1.2 Increased Spend on Healthcare

4.3.1.3 Increase in Europe Wide Diabetic Population

4.3.1.4 Strong contribution to the Biosimilar Market

4.3.1.5 Increase in Cancer Treatment

4.3.1.6 Regulatory Environment

4.4 The Asia Pacific PFS Market 2013-2024

4.4.1 Key drivers of the APAC PFS Market

4.4.1.1 Emerging Middle Classes

4.4.1.2 APAC Diabetes Market

4.4.1.2.1 China Diabetic Market

4.4.1.2.2 India Diabetic Market

4.4.1.2.3 Japanese Diabetic Market

4.4.1.3 Increase in Vaccination demand

4.4.1.3.1 Japanese Vaccination Market

4.4.1.3.2 India Vaccination Market

4.4.1.3.3 China Vaccination Market

4.4.1.4 Growing Cancer Drugs Market Across APAC

4.4.1.4.1 Japanese Cancer Drugs Market

4.4.1.5 Increased Biotechnology Across APAC

4.4.1.5.1 China Biotechnology

4.4.1.5.2 India Biotechnology

4.4.1.5.3 Japan Biotechnology

4.5 The Rest of the World PFS Market 2013-2024

4.5.1 Key drivers of the ROW PFS market

4.5.1.1 Increased demand for Vaccination

4.5.1.1.1 Russian demand for Vaccination

4.5.1.1.2 Brazil Vaccination Landscape

4.5.1.2 Increasing prevalence of Diabetes

4.5.1.2.1 The Brazilian Diabetes Sector

4.5.1.2.2 The Russia Diabetes Sector

4.5.1.3 Increased Healthcare Spending



5 -Leading Therapeutic Segments for Pre-Filled Syringes 2013-2024

5.1 Biologics

5.1.1 Next Generation Biologics

5.1.2 Biologics Pipeline

5.1.3 Key Biologics Exiting Patent

5.2 Biosimilars

5.2.1 Monoclonal Antibodies

5.2.2 Insulin

5.2.3 Erythropoietin

5.2.4 Interferons

5.2.5 G-CSF

5.2.6 Human Growth Hormones

5.3 Vaccines

5.4 Antirheumatics

5.5 Anticoagulants

5.6 Diabetes

5.7 Multiple Sclerosis (MS)



6 - SWOT Analysis of the Global Pre-Filled Syringes Market 2014-2024

6.1 Strengths

6.1.1 Ease of use

6.1.2 Accurate Dosage

6.1.3 Reduced Incidence of Needlestick Injuries

6.1.4 Economic advantages

6.2 Weaknesses

6.2.1 Product stability/compatibility issue

6.2.2 Air bubbles during filling

6.2.3 Device Operation issues

6.2.4 Extractables and Leachables contamination

6.3 Opportunities

6.3.1 Increase in the number of self-injecting patients

6.3.2 Growth of Biologics and Biosimilars

6.3.3 Geographic expansion

6.3.4 Vaccination Programmes

6.3.5 Ageing population

6.4 Threats

6.4.1 Alternative Drug Delivery Platforms

6.4.2 Manufacturing complexities

6.4.3 Manufacturer Recalls

6.4.4 Stringent Regulatory Environment



7 -Company Profiles

7.1. Abbott Labs

7.2: Baxter International

7.3: Becton Dickinson

7.4: Schott AG

7.5. Nipro Corporation

7.6: Gerresheimer AG

7.7. West Pharmaceutical Services

7.8. Ypsomed Holding AG

7.9: Bespak

7.10: Unilife Corporation

7.11: Haselmeier

7.13: Weigao Group

7.14: Owen Mumford



8 -Expert Opinion

8.1 Schott Kaisa

8.2 West Pharmaceuticals

8.3 Fresenius Kabi









Tables

Table 1.4: Drivers and Restraints of the Global Pre-Filled Syringe Market 2014-2024

Table 1.4.2.2: Total Diabetics and Treatment Statistics US, 2013 (million people)

Table 2.2.1: Components of PFS

Table 2.2.2: Key components and description of PFS

Table 2.4.1.1: Advantages of dual-chamber system

Table 2.5.1: Classification of injectors depending upon of the type Use and User

Table 2.5.2.1: Different brands of Insulin available in the market

Table 2.5.3.1: Benefits of Auto-injector

Table 2.5.4.1: Advantages of needle-free

Table 2.5.6.1: Categories of drugs where PFS are used:

Table 3.1.1.2: Breakdown of Pre-filled Syringes market by region, 2013 ($ bn)

Table 3.1.2.1: Pre-filled Syringe Market; Total Revenue, Total Units, Glass Revenue and Plastic Revenue 2013-2024 ($/bn, %)

Table 3.1.2.2: Total Revenue, Total Units, Glass and Plastic 2013, 2014, 2019 and 2024 ($/bn, %)

Table 4.1.1: Global PFS Market Revenue Forecast 2013-2024 ($/bn, %)

Table 4.1.2: Forecast of Regional CAGR 2014-2024 (%)

Table 4.1.3; Regional PFS Market Share Breakdown (%)

Table 4.1.4: Forecast of Regional Market Share 2014, 2019 and 2024 ($/bn and %)

Table 4.1.5: Forecast of Global PFS Revenue and Total Units Shipped 2013-2024 ($/bn and billion units)

Table 4.1.6: Regional PFS Unit Sales (billion)

Table 4.2.1: The North America PFS Market Forecast 2013-2024 ($/bn and AGR %)

Table 4.2.2: The North America PFS Unit Forecast 2013-2024 (billion)

Table 4.2.3: Estimated Incidence, Mortality, and Prevalence of Cancer Worldwide and US - 2012

Table 4.2.4: Total Diabetics and Treatment Statistics, US, 2013 (million people)

4.2.5: Diabetes population, prevalence and healthcare expenditure in the US and Canada (2013)

Table 4.2.6: US Healthcare Spending Per Capita 2000-2013 ($, %)

Table 4.3.1: The Europe PFS Market 2013-2024 ($/bn)

Table 4.3.2: Forecast of European PFS Unit Sales 2013-2024 (Billion Units)

Table 4.3.3 PFS Revenue, by Geography, Europe 2013 ($/ bn / %)

Table 4.3.4: EU5 GDP and Healthcare Spending, 2012 ($/bn)

Table 4.3.5: Diabetes population, prevalence and healthcare expenditure in Europe - 2013 ($)

Table 4.3.6: Estimated Incidence and Mortality rate of Cancer in Europe - 2013

Table 4.4.1: Asia-Pacific and Global PFS Market ($/bn and AGR)

Table 4.4.2: Forecast of Asia-Pacific PFS Unit Sales 2013-2024 (Billion Units)

Table 4.4.3: GDP Growth, India and China 1990-2010 ($/bn, %)

Table 4.4.4: Number of Population with Diabetes in China 2008-2030

Table 4.4.5: China Diabetes Annual Figures, 2013

Table 4.4.6: India Diabetes Annual Figures, 2013

Table 4.4.7: Japan Diabetes Annual Figures, 2013

Table 4.4.8: Incidence, Mortality, and Prevalence of Cancer Worldwide, China, India and Japan 2012

Table 4.4.9: China Pharmaceutical Market for Oncology, 2008 - 2013

Table 4.4.10: APAC Biologics and Biosimilars Market Size 2013 ($/bn)

Table 4.4.11: Key Biosimilars Approved in India 2014

Table 4.4.12: PMDA Approved Biosimilars in Japan 2014

Table 4.5.1: The Rest of the World PFS Market 2013-2024 ($/bn, %)

Table 4.5.2: Forecast of ROW PFS Unit Sales 2013-2024 (Billion Units)

Table 4.5.3; Russian Vaccines Profile 2014

Table 4.5.4: Brazilian Vaccines Profile 2014

Table 4.5.5: Diabetes population, prevalence and healthcare expenditure in Brazil, 2013

Table 4.5.6: Diabetes population, prevalence and healthcare expenditure in Russian, 2013

Table 4.5.7: GDP Growth Brazil and Russia 2000-2010 ($/bn)

Table 4.5.8: Russia and Brazil GDP and Healthcare Spend 2000, 2005 and 2010 ($/bn)

Table 5.1.1: Global Biologics Market Size by Region, 2013 ($/bn)

Table 5.1.2: Biologic medicines under development-by therapeutic category 2014

Table 5.1.3: Biologic medicines under development-by product category 2014

Table 5.1.4: Expiry dates for major patents on best-selling biological products 2011-2024

Table 5.1.5: Key products potential targeted by biosimilar developers post patent expirations

Table 5.2.1: Global Biosimilars Market Size by Region, 2013 ($/bn)

Table 5.2.2: Key Drivers of the Global Biosimilar Market

Table 5.2.3: Key Restraints in the Global Biosimilar Market 2014

Table 5.2.4: Biologics, which lose patent and the opportunity for Biosimilars 2013 ($/bn)

Table 5.2.5: Biologics under different phases of trials

Table 5.3.1: Vaccine manufacturers' classification for supply

Table 5.3.2: Top 10 best-selling vaccine, manufacturer and application 2013

Table 5.5.3: Global Anticoagulants market by region, 2013 ($/bn, %)

Table 5.6.1: Top 10 selling diabetes drugs, 2013

Table 6.1: SWOT Analysis of the Global Pre-filled Syringes Market 2014-2024

Table 6.3.1: Diabetes in the US, Diagnosed, Undiagnosed and New Cases 2012

Table 6.3.2: BRIC Population, Healthcare Expenditure per Capita 2006 / 2012 ($/p/a)

Table 7.1.1: Abbott Labs Key PFS/BGMS Products, 2014

Table 7.2.1: Baxter International Key PFS Products, 2014

Table 7.3.1: Key Becton Dickinson PFS / IV Products, 2014

Table 7.4.1: Schott Key PFS/Needle Products, 2014

Table 7.5.1: Nipro Corporation Key PFS / Related Products, 2014

Table 7.6.1: Gerresheimer Key PFS / Syringe Products, 2014

Table 7.7.1: West Pharmaceutical Key Products, 2014

Table 7.8.1: Ypsomed Key PFS/Injection Products, 2014

Table 7.9.1: Bespak Key PFS / Syringe Products, 2014

Table 8.10.1: Unilife Corporation Key PFS/Injection Products, 2014

Table 7.11.1: Haselmeier Key PFS / Injection Products 2014

Table 7.13.1: Weigao Group Key PFS / Syringe Products, 2014

Table 7.14.1: Owen Mumford Key PFS / Syringe Products, 2014





List of Figures





Figure 2.6.1: Breakdown of Risk of Needlestick Injury 2014

Figure 3.1.1.1: Forecast of the Global Pre-filled Syringes Market, 2013-2024 ($/bn)

Figure 3.1.1.2: Breakdown of Pre-filled Syringes market by region, 2013 ($/bn)

Figure 3.1.2.1: Forecast of the Global Pre-filled Syringes Market, 2013-2024 (bn units)

Figure 3.2.1.1: Forecast of the Global Glass Pre-filled Syringes Market, 2013-2024 ($/bn)

Figure 3.2.2.1: Forecast of the Global Glass Pre-filled Syringes Market, 2013-2024 (bn units)

Figure 3.3.1.1: Forecast of the Global Plastic Pre-filled Syringes Market, 2013-2024 ($/bn)

Figure 3.3.2.1: Forecast of the Global Plastic Pre-filled Syringes Market, 2013-2024 (bn units)

Figure 4.1.1: Global PFS Market Revenue Forecast 2013-2024 ($/bn, %)

Figure 4.1.2 Percentage Share of the Global PFS Market, 2014 (%)

Figure 4.1.3 Percentage Share of the Global PFS Market, 2019 (%)

Figure 4.1.4 Percentage Share of the Global PFS Market, 2024 (%)

Figure 4.2.1 PFS Unit sales, US, (billions) 2013-2024

Figure 4.2.2 US Healthcare Spending Per Capita 2000-2013 ($)

Figure 4.3.1 PFS Unit sales, Europe, (billions) 2013-2024

Figure 4.3.2 PFS Market Revenue, by Geography, Europe, 2013 (%)

Figure 4.3.3: EU5 GDP and Healthcare Spending, 2012 ($/bn)

Figure 4.3.4 China Per Capita Disposable Income 2005-2013 ($)

Figure 4.4.1 PFS Unit sales, ROW, (billions) 2013-2024

Figure 4.4.2 Russia and Brazil Healthcare Spend 2000, 2005 and 2010 ($/bn)

Figure 5.1.1: Global Biologics Market Forecast, 2013-2024 ($/bn)

Figure 5.1.2: Global Biologics Market Size by Region, 2013 ($/bn)

Figure 5.2.1: Global Biosimilar Market Forecast, 2013-2024 ($/bn)

Figure 5.2.2: Global Biosimilar Market Size by Region, 2013 ($/bn)

Figure 5.3.1: Global Vaccine Market Forecast, 2013-2024 ($/bn)

Figure 5.4.1: Global Anti-rheumatics Market Forecast, 2013-2024 ($/bn)

Figure 5.4.2: Market Share of Key Players in Anti-rheumatics Market, 2013 (%)

Figure 5.4.3: Market Share of Key Brands in Anti-rheumatics Market, 2013 (%)

Figure 5.5.1: Global Anticoagulants Market Forecast, 2013-2024 ($/bn)

Figure 5.5.2: Global Anticoagulants Market, by region, 2013 (%)

Figure 5.6.1: Global Anti-diabetic Drugs Market Forecast, 2013-2024 ($/bn)

Figure 5.7.1: Breakdown of Multiple Sclerosis Market, by Region; 2013, ($/bn)

Figure 5.7.2: Forecast of the Global Multiple Sclerosis Market, 2013-2024 ($/bn)

Figure 5.7.3: Top 5 MS Brands, Market Share, 2013

Figure 8.1.1: Abbotts Regional Sales Breakdown, 2013

Figure 8.2.1: Baxter Regional Revenue Breakdown 2013

Figure 8.4.1: Schott's Net Sales, by Region, 2013

Figure 8.5.1: Nipro Regional Net Sale Breakdown, 2013-2014

Figure 8.6.1: Gerresheimer AG Regional Net Sales, 2013-14

Figure 8.7.1: West Pharmaceutical Regional Net Sales, 2013-14




Companies Mentioned
Abbott Labs

AbbVie

Aesica

AesRX LLC (Part of Baxter International)

Amgen

Antares Pharma Inc.

Bausch

Baxter

Bayer

Becton Dickinson

Berlin-Chemie

Biocon

Biogen Idec

Biogen Inc.

Biosensors International Group

BMS

Boehringer Ingelheim

Bracco Diagnostics Inc.

Carl Zeiss Foundation

Cato Software Solutions (Part of BD)

CB Medical Holdings Limited

Cell Science and Technology Institute (Part of Nipro Corporation)

Celltrion

Coherus

Contract Development and Manufacturing Organisation (CDMO)

Daiichi Sanyo

Developing Countries Vaccine Manufacturers Network (DCVMN)

Dong-A Pharmaceutical

Egis

Eli Lilly

European Medicines Agency (EMA)

European Union (EU)

Ferring Pharmaceuticals

Food and Drug Administration (FDA)

Gambro AB (Part of Baxter International)

Genentech

GeneScience Pharmaceuticals

Genzyme

Gerresheimer

GlaxoSmithKline

Globe Medical Tech

Haselmeier

Hospira

Hyaluron Contract manufacturing

International Federation of Pharmaceutical Manufacturers and Association (IFPMA)

Itochu

Johnson and Johnson

Kapoor Glass

Medical Glass (Now a part of Stevanato Group)

Medpro safety Products

Merck and Co.

Merck Serono

Nipro Corporation

Novartis

Novo Nordisk

Nuova Ompi (Stevanato Group)

Ompi of America (Now a part of Stevanato Group)

Owen Mumford Ltd.

Pfizer Australia Pty

Pfizer Inc.

Pharmstandard

Rhone-Poulenc-Rorer

Roche

Sandoz International

Sanofi-Aventis

Schott AG

Schott-Kaisha India

SHL Group

Stevanato group (Nuova Ompi)

Strobel

Takeda

Terumo Europe

Terumo Medical Corp.

Teva Neuroscience

Teva Pharmaceuticals

UB Pharma

UCB

Unilife Corporation

Vetter Pharma

Weigao Group

West Pharmaceuticals Services

Wilco AG

Ypsomed


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.